Johnson & Johnson (JNJ) Raises Quarterly Dividend 5.3% to $1.19; 2.9% Yield

Dow futures rise 135 pts; Bank of America earnings boost sentiment

April 18, 2023 7:21 AM EDT

By Peter Nurse    

Investing.com -- U.S. stocks are seen opening with gains Tuesday, with investors boosted by healthy earnings from Bank of America, continuing the run of U.S. big banks topping estimates. 

At 07:05 ET (11:05 GMT), the Dow Futures contract was up 135 points, or 0.4%, S&P 500 Futures traded 18 points, or 0.4%, higher and Nasdaq 100 Futures climbed 80 points, or 0.6%.

The main indices closed higher Monday as the banking sectors quarterly earnings continued, with Charles Schwab... More

Johnson & Johnson (JNJ) rises on earnings beat, boosted full-year guidance

April 18, 2023 6:41 AM EDT

Johnson & Johnson (NYSE: JNJ) delivered stronger-than-expected Q1 earnings that prompted the healthcare giant to boost its full-year guidance.

JNJ reported a Q1 EPS of $2.68 on revenue of $24.7 billion to top the average analyst estimate for EPS of $2.50 on revenue of $23.61B. Sales rose 5.6%... More

J&J issues cautious 2023 forecast, shares fall

April 18, 2023 6:39 AM EDT

By Bhanvi Satija and Manas Mishra

(Reuters) - Johnson & Johnson on Tuesday cautioned investors over the lingering impact of inflation-driven costs this year as the healthcare conglomerate issued a conservative full-year profit forecast, and its shares fell more than 2%.

J&J also said it expected a steep decline in sales of its blockbuster Crohn's disease drug Stelara once it loses U.S. patent protection in late 2023.

Shares were 2.4% lower at $161.71, making it the biggest decliner on the Dow Jones Industrial Average index, which was off about 0.4%.

J&J, the first large drugmaker and medical device... More

Johnson & Johnson (JNJ) gains 1.8% on beat-and-raise results

April 18, 2023 6:29 AM EDT

Johnson & Johnson (NYSE: JNJ) gains 1.8% on beat-and-raise results:

JNJ reported Q1 EPS of $2.68, $0.18 better than the analyst estimate of $2.50. Revenue for the quarter came in at $24.7 billion versus the consensus estimate of $23.61 billion.JNJ sees FY2023 EPS of $10.60-$10.70, versus the consensus... More

Johnson & Johnson (JNJ) Tops Q1 EPS by 18c; Raises Outlook

April 18, 2023 6:23 AM EDT

Johnson & Johnson (NYSE: JNJ) reported Q1 EPS of $2.68, $0.18 better than the analyst estimate of $2.50. Revenue for the quarter came in at $24.7 billion versus the consensus estimate of $23.61 billion.

GUIDANCE:

Johnson & Johnson sees FY2023 EPS of $10.60-$10.70, versus the consensus of $10.51.... More

J&J talc unit asks judge to halt cancer lawsuits as it pursues $8.9 billion settlement

April 18, 2023 6:07 AM EDT

By Dietrich Knauth

(Reuters) -A Johnson & Johnson subsidiary is again asking a U.S. judge to pause tens of thousands of lawsuits alleging the company's baby powder and other talc products cause cancer, as it seeks to resolve the litigation in bankruptcy after a federal appeals court found its first attempt improper.

At a Tuesday hearing in Trenton, New Jersey, a lawyer for LTL Management argued the lawsuits, which are already stayed against LTL, should also be stopped against J&J, which has a market value of over $430 billion and has not filed for bankruptcy itself.

... More